within Pharmacolibrary.Drugs.ATC.L;

model L04AJ04
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0.25 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 6100 / 1000000,
    adminCount     = 1,
    Vd             = 0.0056,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Sutimlimab is a humanized monoclonal antibody that inhibits complement component C1s. It is used primarily in the treatment of cold agglutinin disease (CAD), a rare autoimmune hemolytic anemia. Sutimlimab is approved for use in adults with CAD to prevent hemolysis.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in adult patients (majority female, mean age ~70 years) with cold agglutinin disease after intravenous administration.</p><h4>References</h4><ol><li><p>Bartko, J, et al., &amp; Jilma, B (2018). A Randomized, First-in-Human, Healthy Volunteer Trial of sutimlimab, a Humanized Antibody for the Specific Inhibition of the Classical Complement Pathway. <i>Clinical pharmacology and therapeutics</i> 104(4) 655â€“663. DOI:<a href=&quot;https://doi.org/10.1002/cpt.1111&quot;>10.1002/cpt.1111</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/29737533/&quot;>https://pubmed.ncbi.nlm.nih.gov/29737533</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end L04AJ04;
